Emerging evidence suggests that the catalytically inactive ErbB3 (HER3) protein plays a fundamental role in normal tyrosine kinase receptor signaling as well as in aberrant functioning of these signaling pathways, resulting in several forms of human cancers and some mental disorders. Here we report the generation of a specific anti-ErbB3 antibody intended for use in diagnosing disease or therapeutic application. By using the hybridoma technique, one cell line (2E12C3) stably producing anti-ErbB3 antibody was obtained. Its molecular weight was about 185 kDa and its isotype was IgG 2a and κ, respectively. The affinity constant (Kaff) of the anti-ErbB3 MAb was 5.83×1010 M−1. This antibody may become a useful tool for diagnostic and therapeutic targeting of ErbB3-expressing cancers or helpful in highlighting the etiology of schizophrenia.
Get full access to this article
View all access options for this article.
References
1.
AlroyI, YardenY. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand–receptor interactions. FEBS Lett, 1997; 410,1:83–86.
2.
CitriA, SkariaKB, YardenY. The deaf and the dumb: the biology of ErbB-2 and ErbB-3 [review]Exp Cell Res, 2003; 284,1:54–65.
3.
HynesNE, LaneHA. ERBB receptors and cancer: the complexity of targeted inhibitors [review]Nat Rev Cancer, 2005; 5,5:341–54.
HellyerNJ, KimMS, KolandJG. Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor. J Biol Chem, 2001; 276,45:42153–42161.
6.
LiJ, AdamR M, SantiestevanE, FreemanM R. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res, 1999; 59,12:2891–2897.
7.
SchoeberlB, PaceEA, FitzgeraldJB, HarmsBD, XuL, NieL, LinggiB, KalraA, ParagasV, BukhalidR, GrantcharovaV, KohliN, WestKA, LeszczynieckaM, FeldhausMJ, KudlaAJ, NielsenUB. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal, 2009; 2,77:ra31.
8.
StoveC, BrackeM. Roles for neuregulins in human cancer [review]Clin Exp Metastasis, 2004; 21,8:665–684.
9.
HuangX, GaoL, WangS, McManamanJL, ThorAD, YangX, EstevaFJ, LiuB. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res, 2010; 70,3:1204–1214.
10.
ReschkeM, Mihic-ProbstD, van der HorstEH, KnyazevP, WildPJ, HuttererM, MeyerS, DummerR, MochH, UllrichA. HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res, 2008; 14,16:5188–5197.
11.
SingerE, LandgrafR, HoranT, SlamonD, EisenbergD. Identification of a heregulin binding site in HER3 extracellular domain. J Biol Chem, 2001; 276,47:44266–44274.
CorfasG, RoyK, BuxbaumJD. Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia [review]Nat Neurosci, 2004; 7,6:575–580.
15.
WatanabeY, FukuiN, NunokawaA, MuratakeT, KanekoN, KitamuraH, SomeyaT. No association between the ERBB3 gene and schizophrenia in a Japanese population. Neurosci Res, 2007; 57,4:574–578.
SchotsA, Van der LeedeBJ, De JonghE, EgbertsE. A method for the determination of antibody affinity using a direct ELISA. J Immunol Methods, 1988; 109,2:225–233.
18.
BeattyJD, BeattyBG, VlahosWG. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods, 1987; 100,1–2:173–179.
19.
HsiehSY, HeJR, YuMC, LeeWC, ChenTC, LoSJ, BeraR, SungCM, ChiuCT. Secreted ERBB3 isoforms are serum markers for early hepatoma in patients with chronic hepatitis and cirrhosis. J Proteome Res, 2011; 10,10:4715–4724.
20.
HakakY, WalkerJR, LiC, WongWH, DavisKL, BuxbaumJD, HaroutunianV, FienbergAA. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA, 2001; 98,8:4746–4751.
21.
MeiL, XiongWC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci, 2008; 9,6:437–452.
